cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Relay Therapeutics Inc
8 own
4 watching
Current Price
$4.89
$-0.03
(-0.61%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,164.86M
52-Week High
52-Week High
11.16000
52-Week Low
52-Week Low
3.5
Average Volume
Average Volume
2.22M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,164.86M
icon52-Week High11.16000
icon52-Week Low3.5
iconAverage Volume2.22M
iconDividend Yield--
iconP/E Ratio--
What does the Relay Therapeutics Inc do?
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.
Read More
How much money does Relay Therapeutics Inc make?
News & Events about Relay Therapeutics Inc.
Benzinga
1 year ago
Latest Ratings for RLAY DateFirmActionFromTo Feb 2022BerenbergInitiates Coverage OnBuy Aug 2021HC Wainwright & Co.MaintainsBuy Jul 2021B of A SecuritiesInitiates Coverage OnBuy View More Analyst Ratings for RLAY View the Latest Analyst Ratings read more...
Globe Newswire
1 year ago
Multiple doses achieved sustained target exposure of ~80%+ mutant PI3K inhibition No Grade 3 hyperglycemia, rash or diarrhea observed at target exposures Favorable initial safety profile at target exposures Confirmed partial response in breast cancer patient with 12 prior lines of therapy Initial ...
PR Newswire
1 year ago
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer PR Newswire VANCOUVER, British Columbia, March 24, 2023 FN Media Group Presents USA News Group News Commentary VANCOUVER...
Globe Newswire
1 year ago
Relay Therapeutics to host conference call following AACR presentationCAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and ...
Globe Newswire
1 year ago
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month, at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET and the Barclays Global Healthcare Conference on ...
Frequently Asked Questions
Frequently Asked Questions
What is Relay Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Relay Therapeutics Inc shares?
plus_minus_icon
How can I buy Relay Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Relay Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Relay Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Relay Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Relay Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Relay Therapeutics Inc?
plus_minus_icon
What percentage is Relay Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Relay Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.89
$-0.03
(-0.61%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$45.40
$-1.33 (-2.85 %)
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$77.60
$-1.99 (-2.50 %)
CABALETTA BIO INC
CABALETTA BIO INC
$2.59
$0.05 (1.97 %)
Applied Therapeutics Inc
Applied Therapeutics Inc
$0.61
$-0.01 (-2.28 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$45.40
$-1.33 (-2.85 %)
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$77.60
$-1.99 (-2.50 %)
CABALETTA BIO INC
CABALETTA BIO INC
$2.59
$0.05 (1.97 %)
Applied Therapeutics Inc
Applied Therapeutics Inc
$0.61
$-0.01 (-2.28 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00